A Study to Learn About the Study Medicine Zavicefta After it is Released Into the Markets in Korea
← catalyst calendarNCT05733104 · readout in 1,136 d
Sponsored by Pfizer (industry) · PFE — their whole pipeline →.
Phase
—
Status
Recruiting
Study type
Observational
Enrollment
600estimated
Sites
1
Country
South Korea
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2024-02-19 | actual | When the study began enrolling |
| Primary completion | 2029-09-28 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2029-09-28 | estimated | The whole study's end, after follow-up |
| First posted | 2023-02-17 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2025-09-03 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Conditions
- Complicated Intra-abdominal Infection
- Complicated Urinary Tract Infection
- Hospital-acquired Pneumonia
Primary outcome
what the primary-completion date above is the date OFNumber of patient reporting an adverse event
measured From first dose to end of the observation period (at least 28 calendar days following the last dose)
Permalink · PFE's whole pipeline · Catalyst calendar · Every registered study · What changed